Chapter 3 Cellular and Molecular Mechanisms in Atopic Dermatitis

Oyoshi, Michiko K.; He, Rui; Kumar, Lalit; Yoon, Jeong‐Won; Geha, Raif S.

doi:10.1016/s0065-2776(09)01203-6

Cited by 221 publications

(227 citation statements)

References 364 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…Perhaps the previous observations made by these LC pioneers were dendrites of activated LCs that had docked with TJs. entered the skin at the time of Ag uptake (McGrath and Uitto, 2008;Oyoshi et al, 2009). In this study, we demonstrate that activated LCs gain access to extra-TJ Ags by sending their dendrites out through epidermal TJs.…”

Section: Br Ief Definitive Repor Tmentioning

confidence: 56%

External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers

Kubo¹,

Nagao²,

Yokouchi³

et al. 2009

J Cell Biol

143

View full text Add to dashboard Cite

Section: Br Ief Definitive Repor Tmentioning

confidence: 56%

External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers

Kubo¹,

Nagao²,

Yokouchi³

et al. 2009

J Cell Biol

143

View full text Add to dashboard Cite

“…S. aureus colonizes the skin of 70–90% of patients with AD, in contrast to only 5% of normal population 14, 15. This is due to a defect in skin barrier function, repeated scratching, and deficient cutaneous antimicrobial peptides 16.…”

Section: Introductionmentioning

confidence: 99%

Honey is potentially effective in the treatment of atopic dermatitis: Clinical and mechanistic studies

Alangari

Morris

Lwaleed

et al. 2017

Immunity, Inflammation and Disease

View full text Add to dashboard Cite

IntroductionAs manuka honey (MH) exhibits immunoregulatory and anti‐staphylococcal activities, we aimed to investigate if it could be effective in the treatment of atopic dermatitis (AD).MethodsAdult volunteers with bilateral AD lesions were asked to apply MH on one site overnight for seven consecutive days and leave the contralateral site untreated as possible. Three Item Severity score was used to evaluate the response. Skin swabs were obtained from both sites before and after treatment to investigate the presence of staphylococci and enterotoxin production. In addition, the ability of MH and its methanolic and hexane extracts to down regulate IL4‐induced CCL26 protein release from HaCaT cells was evaluated by enzyme linked immunosorbent assay. Also, the ability of MH to modulate calcium ionophore‐induced mast cell degranulation was assessed by enzyme immunoassay.ResultsIn 14 patients, AD lesions significantly improved post MH treatment versus pre‐treatment as compared to control lesions. No significant changes in the skin staphylococci were observed after day 7, irrespective of honey treatment. Consistent with the clinical observation, MH significantly down regulated IL4‐induced CCL26 release from HaCaT cells in a dose‐dependent manner. This effect was partially lost, though remained significant, when methanolic and hexane extracts of MH were utilized. In addition, mast cell degranulation was significantly inhibited following treatment with MH.ConclusionsMH is potentially effective in the treatment of AD lesions based on both clinical and cellular studies through different mechanisms. This needs to be confirmed by randomized and controlled clinical trials.

show abstract

“…Thus, the use of DCs to control cancer and infectious diseases has been proposed (4). However, DCs are also involved in the pathogenesis of several diseases caused by immune dysfunction, such as chronic inflammation and autoimmunity (5,6). Substances downregulating DC activation can potentially be applied to the treatment of these diseases.…”

mentioning

confidence: 99%